Literature DB >> 31161828

Developing a preference-based utility scoring algorithm for the Psoriasis Area Severity Index (PASI).

Louis S Matza1, John E Brazier2, Katie D Stewart1, Lionel Pinto3, Randall H Bender4, Leon Kircik5, Jessica Jordan1, Katherine J Kim4, Alex Mutebi6, Hema N Viswanathan6, Alan Menter7.   

Abstract

Introduction: It is challenging to identify health state utilities associated with psoriasis because generic preference-based measures may not capture the impact of dermatological symptoms. The Psoriasis Area Severity Index (PASI) is one of the most commonly used psoriasis rating scales in clinical trials. The purpose of this study was to develop a utility scoring algorithm for the PASI.
Methods: Forty health states were developed based on PASI scores of 40 clinical trial patients. Health states were valued in time trade-off interviews with UK general population participants. Regression models were conducted to crosswalk from PASI scores to utilities (e.g. OLS linear, random effects, mean, robust, spline, quadratic).
Results: A total of 245 participants completed utility interviews (51.4% female; mean age = 45.3 years). Models predicting utility based on the four PASI location scores (head, upper limbs, trunk, lower limbs) had better fit/accuracy (e.g. R2, mean absolute error [MAE]) than models using the PASI total score. Head/upper limb scores were more strongly associated with utility than trunk/lower limb. The recommended model is the OLS linear model based on the four PASI location scores (R2 = 0.13; MAE = 0.03). An alternative is recommended for situations when it is necessary to estimate utility based on the PASI total score. Conclusions: The derived scoring algorithm may be used to estimate utilities based on PASI scores of any treatment group with psoriasis. Because the PASI is commonly used in psoriasis clinical trials, this scoring algorithm greatly expands options for quantifying treatment outcomes in cost-effectiveness analyses of psoriasis therapies. Results indicate that psoriasis of the head/upper limbs could be more important than trunk/lower limbs, suggesting reconsideration of the standard PASI scoring approach.

Entities:  

Keywords:  Health state utilities; I10; I19; Psoriasis Area Severity Index (PASI); condition-specific preference-based measure; psoriasis; time trade-off

Mesh:

Year:  2019        PMID: 31161828     DOI: 10.1080/13696998.2019.1627362

Source DB:  PubMed          Journal:  J Med Econ        ISSN: 1369-6998            Impact factor:   2.448


  3 in total

1.  Transdermal Permeation Assays of Curcumin Aided by CAGE-IL: In Vivo Control of Psoriasis.

Authors:  Rodrigo Boscariol; Érika A Caetano; Denise Grotto; Raquel M Rosa-Castro; José M Oliveira Junior; Marta M D C Vila; Victor M Balcão
Journal:  Pharmaceutics       Date:  2022-04-02       Impact factor: 6.525

2.  Variation at ACOT12 and CT62 locus represents susceptibility to psoriasis in Han population.

Authors:  Jianxiao Xing; Xincheng Zhao; Xiaofang Li; Ying Wang; Junqin Li; Ruixia Hou; Xuping Niu; Guohua Yin; Xinhua Li; Kaiming Zhang
Journal:  Mol Genet Genomic Med       Date:  2019-12-20       Impact factor: 2.183

3.  Biologics for severe, chronic plaque psoriasis: An Australian cost-utility analysis.

Authors:  Helen Y Sun; Elena Keller; Harish Suresh; Deshan F Sebaratnam
Journal:  JAAD Int       Date:  2021-08-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.